Contributor Page
Shelston IP
Email  |  Website  |  Articles
Contact Details
Tel: +61 2 97771111
Fax: +61 2 92414666
Level 21
60 Margaret Street
By Duncan Longstaff, Mark Vincent, Natasha Faigenbaum
The decision clarifies what is needed to receive damages in a claim for unjustified threats of infringement proceedings.
By Duncan Longstaff, Jacinta Flattery-O'Brien
This case set a new benchmark in Australia for future patent infringement damages claims against generic manufacturers.
By Duncan Longstaff, Jacinta Flattery-O'Brien
We discuss Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285.
By Mary Munroe, Paul Harrison
These changes are intended to simplify, clarify and bring greater certainty to users of the UK patent system.
By Grant Shoebridge
This Productivity Commission report evoked a range of conflicting views as to the best policy to incentivise innovation.
By Serena White DPhil, Katrina Crooks
We look at poisonous priority and partial priority and the legal approaches to these issues in different jurisdictions.
By Gareth Dixon
Nearly four years ago, on 15 April 2013, Australian patent law entered a brave new world.
By Kieran Williams, Jacinta Flattery-O'Brien
This recent decision highlights the importance of including Swiss-style claims in Australian pharmaceutical patents.
By Kathy Mytton, Gerard Skelly
The appeal against the decision refusing registration of its application for trademark registration was unsuccessful.
By Duncan Longstaff
This outcome is likely to restrict the marketing activities of potential infringers in the lead-up to the patent expiry.
By Mark Vincent
The new laws will cover most Australian Government agencies and many private sector and not-for-profit organisations.
By Duncan Longstaff, Katrina Crooks
Welcome to Shelston IP's round-up of the best and most significant patent cases from Australia delivered during 2016.
By Charles Tansey, Mary Munroe
The deal brokered between the EPO and the Cambodian government was announced on 23 January 2017.
By Michael Deacon, Chris Bevitt
This case considered non-use of trademarks.
By Michael Deacon, Chris Bevitt
An owner of a trade mark which is at risk of becoming generic must actively manage its own use of the trade mark.
Contributor's Topics